HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) 061549.Supplemental Data All Versions of this Article: clinchem.2005.061549v1 52/6/1104    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (3) Citing Articles via Google Scholar Google Scholar Articles by Mørkbak, A. L. Articles by Nexø, E. Search for Related Content PubMed PubMed Citation Articles by Mørkbak, A. L. Articles by Nexø, E. Related Collections General Clinical Chemistry Nutrition Endocrinology and Metabolism

Effect of Vitamin B₁₂ Treatment on Haptocorrin

¹ Department of Clinical Biochemistry, Aarhus Sygehus, and² Department of Clinical Biochemistry, Skejby Sygehus, Aarhus University Hospital, Aarhus, Denmark.
³ Nutrition, Food and Health Research Centre, King’s College, London, United Kingdom.
⁴ Department of Heart Disease, Haukeland University Hospital, Bergen, Norway.
⁵ Institute of Medicine, University of Bergen, Bergen, Norway.
⁶ Institute of Basic Medical Sciences, Department of Nutrition, University of Oslo, Oslo, Norway.

^aAddress correspondence to this author at: Department of Clinical Biochemistry, Nørrebrogade, Aarhus Sygehus, Aarhus University Hospital, Nørrebrogade 44, DK 8000 Aarhus, Denmark. Fax 45-89-49-30-60; e-mail almor{at}as.aaa.dk.

Background: Haptocorrin (HC) carries the major part of circulating cobalamin, but whether HC is altered on treatment with vitamin B₁₂ remains unknown.

Methods: Our study included 3 populations: a population of vegan men (n = 174; vegan population), of whom 63 were treated daily with 5 mg of oral vitamin B₁₂ for 3 months; a group of patients with a previous methylmalonic acid (MMA) concentration >0.4 µmol/L (n = 140; population with suspected deficiency), of which 69 were treated with weekly vitamin B₁₂ injections (1 mg) for 4 weeks; and a subgroup of participants in a vitamin B intervention study (n = 88; nondeficient population), of whom 45 were treated daily with 0.4 mg of oral vitamin B₁₂ for 3 months. Total HC and holoHC were measured by ELISA. Cobalamin was measured by an intrinsic factor (IF)-based assay. Samples were collected at baseline and 3 months after start of treatment.

Results: Compared with baseline results for the 3 study populations, total HC and holoHC increased 30 pmol/L for every 100 pmol/L increase in cobalamin. After treatment with vitamin B₁₂, holoHC (P <0.0001) and total HC (P <0.0001) increased significantly in the vegan population. Only holoHC increased in the population with suspected deficiency (P <0.0001), whereas no alteration was observed in the nondeficient population.

Conclusions: The HC concentration is decreased in severely cobalamin-deficient individuals and increases on treatment. The concentration of cobalamin also relates significantly to the HC concentration in nondeficient individuals.

The following articles in journals at HighWire Press have cited this article:

				N. Dali-Youcef and E. Andres An update on cobalamin deficiency in adults QJM, January 1, 2009; 102(1): 17 - 28. [Abstract] [Full Text] [PDF]

				R. Carmel Haptocorrin (Transcobalamin I) and Cobalamin Deficiencies Clin. Chem., February 1, 2007; 53(2): 367 - 368. [Full Text] [PDF]

				A. L. Morkbak and E. Nexo The authors of the article cited above respond: Clin. Chem., February 1, 2007; 53(2): 368 - 369. [Full Text] [PDF]